Braun Stacey Associates Inc. Has $6.61 Million Position in Boston Scientific Corporation $BSX

Braun Stacey Associates Inc. cut its holdings in Boston Scientific Corporation (NYSE:BSX) by 59.0% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 105,341 shares of the medical equipment provider’s stock after selling 151,752 shares during the period. Braun Stacey Associates Inc.’s holdings in Boston Scientific were worth $6,610,000 as of its most recent filing with the SEC.

Several other large investors have also made changes to their positions in BSX. Cambient Family Office LLC boosted its stake in Boston Scientific by 30.1% during the 1st quarter. Cambient Family Office LLC now owns 3,699 shares of the medical equipment provider’s stock valued at $232,000 after purchasing an additional 855 shares during the period. Pinnacle Wealth Management Advisory Group LLC increased its position in Boston Scientific by 56.9% in the 1st quarter. Pinnacle Wealth Management Advisory Group LLC now owns 8,452 shares of the medical equipment provider’s stock worth $530,000 after buying an additional 3,065 shares during the period. VCI Wealth Management LLC lifted its holdings in shares of Boston Scientific by 55.2% during the first quarter. VCI Wealth Management LLC now owns 24,261 shares of the medical equipment provider’s stock worth $1,522,000 after buying an additional 8,632 shares during the last quarter. Generali Investments Towarzystwo Funduszy Inwestycyjnych lifted its holdings in shares of Boston Scientific by 72.7% during the first quarter. Generali Investments Towarzystwo Funduszy Inwestycyjnych now owns 38,000 shares of the medical equipment provider’s stock worth $2,384,000 after buying an additional 16,000 shares during the last quarter. Finally, OLD National Bancorp IN boosted its position in shares of Boston Scientific by 193.0% in the first quarter. OLD National Bancorp IN now owns 6,320 shares of the medical equipment provider’s stock valued at $397,000 after acquiring an additional 4,163 shares during the period. Institutional investors and hedge funds own 89.07% of the company’s stock.

Boston Scientific Stock Performance

BSX opened at $44.16 on Friday. The stock has a market cap of $65.64 billion, a PE ratio of 18.48, a P/E/G ratio of 0.85 and a beta of 0.56. The company has a current ratio of 1.90, a quick ratio of 1.22 and a debt-to-equity ratio of 0.42. Boston Scientific Corporation has a 1 year low of $43.89 and a 1 year high of $109.50. The stock’s 50 day simple moving average is $52.87 and its 200-day simple moving average is $71.13.

Boston Scientific (NYSE:BSX) last issued its earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 EPS for the quarter, beating analysts’ consensus estimates of $0.79 by $0.01. The business had revenue of $5.20 billion during the quarter, compared to analyst estimates of $5.19 billion. Boston Scientific had a return on equity of 19.17% and a net margin of 17.29%.Boston Scientific’s revenue was up 11.6% on a year-over-year basis. During the same period in the prior year, the company posted $0.75 earnings per share. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. Sell-side analysts forecast that Boston Scientific Corporation will post 3.36 EPS for the current year.

Boston Scientific announced that its board has authorized a share repurchase plan on Monday, May 18th that authorizes the company to buyback $5.00 billion in outstanding shares. This buyback authorization authorizes the medical equipment provider to purchase up to 6.4% of its shares through open market purchases. Shares buyback plans are typically a sign that the company’s management believes its shares are undervalued.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on BSX. Jefferies Financial Group lowered their price objective on shares of Boston Scientific from $100.00 to $67.00 and set a “buy” rating on the stock in a research note on Wednesday. Weiss Ratings cut shares of Boston Scientific from a “hold (c)” rating to a “hold (c-)” rating in a research note on Wednesday, May 13th. Bank of America reduced their price target on shares of Boston Scientific from $105.00 to $68.00 and set a “buy” rating for the company in a report on Monday, May 18th. Wolfe Research lowered shares of Boston Scientific from an “outperform” rating to a “peer perform” rating in a research report on Friday, May 29th. Finally, Needham & Company LLC restated a “buy” rating and set a $77.00 price objective on shares of Boston Scientific in a report on Monday, May 18th. One analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, five have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $83.36.

Insider Activity

In other Boston Scientific news, Director David C. Habiger bought 2,250 shares of the firm’s stock in a transaction dated Wednesday, May 20th. The shares were acquired at an average cost of $55.92 per share, for a total transaction of $125,820.00. Following the transaction, the director owned 13,878 shares in the company, valued at approximately $776,057.76. The trade was a 19.35% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Edward J. Ludwig bought 3,580 shares of the stock in a transaction that occurred on Wednesday, May 20th. The stock was acquired at an average cost of $56.68 per share, for a total transaction of $202,914.40. Following the purchase, the director owned 25,359 shares of the company’s stock, valued at $1,437,348.12. This trade represents a 16.44% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. In the last 90 days, insiders acquired 9,800 shares of company stock worth $554,012. 0.34% of the stock is currently owned by corporate insiders.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.